AP662A - Anhydrous crystalline valaciclovir hydrochloride. - Google Patents

Anhydrous crystalline valaciclovir hydrochloride. Download PDF

Info

Publication number
AP662A
AP662A APAP/P/1997/001058A AP9701058A AP662A AP 662 A AP662 A AP 662A AP 9701058 A AP9701058 A AP 9701058A AP 662 A AP662 A AP 662A
Authority
AP
ARIPO
Prior art keywords
valaciclovir
hydrochloride
valaciclovir hydrochloride
crystalline
anhydrous crystalline
Prior art date
Application number
APAP/P/1997/001058A
Other languages
English (en)
Other versions
AP9701058A0 (en
Inventor
Carter Barry Howard
Partin Jane Muse
Varlashkin Peter Gregory
Winnike Richard Augustus
Grubb William Bayne
Conway Gregory Alan
Lake Philip George
Skinner David Michael
Whatrup David James
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP662(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9701058A0 publication Critical patent/AP9701058A0/xx
Application granted granted Critical
Publication of AP662A publication Critical patent/AP662A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001058A 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride. AP662A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
AP9701058A0 AP9701058A0 (en) 1997-10-31
AP662A true AP662A (en) 1998-08-19

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001058A AP662A (en) 1995-01-20 1996-01-19 Anhydrous crystalline valaciclovir hydrochloride.

Country Status (40)

Country Link
US (1) US6107302A (enEXAMPLES)
EP (1) EP0804436B1 (enEXAMPLES)
JP (1) JP3176633B2 (enEXAMPLES)
KR (1) KR100376074B1 (enEXAMPLES)
CN (1) CN1049893C (enEXAMPLES)
AP (1) AP662A (enEXAMPLES)
AR (1) AR002270A1 (enEXAMPLES)
AT (1) ATE302777T1 (enEXAMPLES)
AU (1) AU702794B2 (enEXAMPLES)
BG (1) BG63393B1 (enEXAMPLES)
BR (1) BR9606768A (enEXAMPLES)
CA (1) CA2210799C (enEXAMPLES)
CY (1) CY2531B1 (enEXAMPLES)
CZ (1) CZ297065B6 (enEXAMPLES)
DE (1) DE69635106T2 (enEXAMPLES)
DK (1) DK0804436T3 (enEXAMPLES)
EA (1) EA000364B1 (enEXAMPLES)
EE (1) EE03528B1 (enEXAMPLES)
ES (1) ES2248806T3 (enEXAMPLES)
FI (1) FI973063L (enEXAMPLES)
GB (1) GB9501178D0 (enEXAMPLES)
GE (1) GEP20001940B (enEXAMPLES)
HR (1) HRP960024B1 (enEXAMPLES)
HU (1) HU222993B1 (enEXAMPLES)
IL (1) IL116831A (enEXAMPLES)
IN (1) IN182468B (enEXAMPLES)
IS (1) IS2268B (enEXAMPLES)
NO (1) NO315558B1 (enEXAMPLES)
NZ (1) NZ298851A (enEXAMPLES)
OA (1) OA10499A (enEXAMPLES)
PL (1) PL182175B1 (enEXAMPLES)
RO (1) RO118693B1 (enEXAMPLES)
RS (1) RS49518B (enEXAMPLES)
SI (1) SI0804436T1 (enEXAMPLES)
SK (1) SK285329B6 (enEXAMPLES)
TR (1) TR199700656T1 (enEXAMPLES)
UA (1) UA46001C2 (enEXAMPLES)
UY (1) UY25779A1 (enEXAMPLES)
WO (1) WO1996022291A1 (enEXAMPLES)
ZA (1) ZA96449B (enEXAMPLES)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
EP0874631B1 (en) * 1996-01-19 2003-11-19 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
CN1250449A (zh) * 1997-01-17 2000-04-12 味之素株式会社 新型z-伐昔洛韦结晶
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
RS55023B1 (sr) * 2001-02-24 2016-11-30 Boehringer Ingelheim Pharma Derivati ksantina, njihovo dobijanje i njihova primena kao lekova
KR100774271B1 (ko) * 2001-09-07 2007-11-08 테바 파마슈티컬 인더스트리즈 리미티드 발라사이클로비르 염산염의 결정질 형태
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
PL371732A1 (en) * 2001-11-14 2005-06-27 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
US20050085491A1 (en) * 2003-06-02 2005-04-21 Igor Lifshitz Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP3725325B1 (en) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US20140296520A1 (en) * 2011-11-25 2014-10-02 Piramal Enterprises Limited Process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽(常州)药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065B1 (en) * 1987-08-15 1995-01-04 The Wellcome Foundation Limited Therapeutic nucleosides
EP0596542B1 (en) * 1987-08-15 1996-05-29 The Wellcome Foundation Limited Therapeutic nucleosides
WO1994029311A1 (en) * 1993-06-10 1994-12-22 Farmhispania Sa Amino acid ester of nucleoside analogues
WO1996022291A1 (en) * 1995-01-20 1996-07-25 The Wellcome Foundation Limited Guanine derivative

Also Published As

Publication number Publication date
HRP960024B1 (en) 2005-08-31
EP0804436A1 (en) 1997-11-05
IS4527A (is) 1997-07-15
IL116831A0 (en) 1996-05-14
FI973063A7 (fi) 1997-09-18
RS49518B (sr) 2006-10-27
EA000364B1 (ru) 1999-06-24
SK285329B6 (sk) 2006-11-03
JP3176633B2 (ja) 2001-06-18
AR002270A1 (es) 1998-03-11
CN1179159A (zh) 1998-04-15
YU3396A (sh) 1998-12-23
SK96597A3 (en) 1998-02-04
CZ229497A3 (en) 1997-12-17
GB9501178D0 (en) 1995-03-08
DE69635106D1 (de) 2005-09-29
BG101833A (bg) 1998-04-30
KR19980701525A (ko) 1998-05-15
OA10499A (en) 2002-04-10
TR199700656T1 (xx) 1998-03-21
NO973326L (no) 1997-09-16
US6107302A (en) 2000-08-22
IN182468B (enEXAMPLES) 1999-04-17
FI973063L (fi) 1997-09-18
PL182175B1 (pl) 2001-11-30
AP9701058A0 (en) 1997-10-31
SI0804436T1 (sl) 2006-02-28
WO1996022291A1 (en) 1996-07-25
CA2210799C (en) 2008-06-10
AU702794B2 (en) 1999-03-04
HU222993B1 (hu) 2004-01-28
ES2248806T3 (es) 2006-03-16
PL321326A1 (en) 1997-12-08
EP0804436B1 (en) 2005-08-24
HUP9801836A2 (hu) 1999-05-28
CZ297065B6 (cs) 2006-08-16
IL116831A (en) 1998-10-30
DE69635106T2 (de) 2006-06-08
CY2531B1 (en) 2006-04-12
UA46001C2 (uk) 2002-05-15
RO118693B1 (ro) 2003-09-30
MX9705462A (es) 1997-10-31
JPH11503718A (ja) 1999-03-30
FI973063A0 (fi) 1997-07-18
KR100376074B1 (ko) 2003-06-02
AU4453996A (en) 1996-08-07
HRP960024A2 (en) 1997-10-31
CA2210799A1 (en) 1996-07-25
EE03528B1 (et) 2001-10-15
ZA96449B (en) 1996-08-07
CN1049893C (zh) 2000-03-01
NO315558B1 (no) 2003-09-22
BR9606768A (pt) 1997-12-30
ATE302777T1 (de) 2005-09-15
UY25779A1 (es) 2000-08-21
HUP9801836A3 (en) 1999-06-28
NO973326D0 (no) 1997-07-18
BG63393B1 (bg) 2001-12-29
EE9700175A (et) 1998-02-16
DK0804436T3 (da) 2005-12-27
GEP20001940B (en) 2000-02-05
IS2268B (is) 2007-07-15
NZ298851A (en) 1999-01-28
EA199700124A1 (ru) 1997-12-30

Similar Documents

Publication Publication Date Title
AP662A (en) Anhydrous crystalline valaciclovir hydrochloride.
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
CA2243237C (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005462A (en) Derived from guan
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color